Session 5: CIT
Tracks
Plenary Hall
| Friday, March 27, 2026 |
| 4:30 PM - 5:45 PM |
Speaker
Dr. Hanny Al- Samkari
Associate Professor of Medicine, Harvard Medical School
The Peggy S. Blitz Endowed Chair in Hematology/Oncology, Massachusetts General Hospital
Advances in Chemotherapy-Induced Thrombocytopenia (CIT)
4:30 PM - 5:00 PMBiography
Hanny Al-Samkari, M.D. is a classical hematologist and leading international clinical investigator in hemostasis, platelet disorders, and hemolytic anemias. His focus is on the development of novel therapeutics in hereditary hemorrhagic telangiectasia, immune thrombocytopenia, chemotherapy-induced thrombocytopenia and hemolytic anemia. He serves as global principal investigator for many ongoing studies in these areas.
Dr. Hanny Al- Samkari
Associate Professor of Medicine, Harvard Medical School
The Peggy S. Blitz Endowed Chair in Hematology/Oncology, Massachusetts General Hospital
Optimal Use of Thrombopoietin Receptor Agonists on ITP or on Thromboembolism in ITP
5:00 PM - 5:40 PMBiography
Hanny Al-Samkari, M.D. is a classical hematologist and leading international clinical investigator in hemostasis, platelet disorders, and hemolytic anemias. His focus is on the development of novel therapeutics in hereditary hemorrhagic telangiectasia, immune thrombocytopenia, chemotherapy-induced thrombocytopenia and hemolytic anemia. He serves as global principal investigator for many ongoing studies in these areas.
Session Chair
Muna Al Rasheed
Consultant, Head of clinical hematology unit
Adan Hospital, MOH
